Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» non-small cell lung cancer
non-small cell lung cancer
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Fierce Biotech
Thu, 03/16/23 - 07:02 pm
Merck
Keytruda
clinical trials
vibostolimab
non-small cell lung cancer
metastatic non-small cell lung cancer
Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec
Fierce Pharma
Mon, 12/19/22 - 12:29 pm
AstraZeneca
Imfinzi
lung cancer
non-small cell lung cancer
With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta
Fierce Pharma
Mon, 12/19/22 - 11:02 am
Eagle Pharmaceuticals
Pemfexy
Eli Lilly
mesothelioma
non-small cell lung cancer
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
BioSpace
Sun, 12/4/22 - 01:17 pm
Mirati Therapeutics
clinical trials
M&A
non-small cell lung cancer
sitravantinib
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Thu, 12/1/22 - 07:11 pm
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial
Fierce Pharma
Thu, 12/1/22 - 10:55 am
Roche
Tecentriq
clinical trials
non-small cell lung cancer
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance
Fierce Pharma
Wed, 11/30/22 - 07:58 pm
GSK
Merck
Jemperli
Keytruda
clinical trials
non-small cell lung cancer
Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease
Fierce Biotech
Mon, 11/28/22 - 07:37 pm
Gilead Sciences
Arcus Biosciences
clinical trials
domvanalimab
zimberelimab
non-small cell lung cancer
Lyvgen and BMS partner for Phase II lung cancer antibody trial
Clinical Trials Arena
Mon, 11/28/22 - 10:18 am
Lyvgen
Bristol Myers Squibb
clinical trials
LVGN7409
non-small cell lung cancer
AZ claims another Imjudo approval, in big first-line NSCLC market
Pharmaphorum
Fri, 11/11/22 - 10:53 am
AstraZeneca
FDA
Imjudo
non-small cell lung cancer
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Endpoints
Wed, 11/9/22 - 10:38 am
Regeneron
Libtayo
non-small cell lung cancer
Keytruda
Merck
Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda
Fierce Biotech
Thu, 11/3/22 - 11:10 am
Gilead Sciences
ARCUS
clinical trials
Merck
Keytruda
domvanalimab
zimberelimab
non-small cell lung cancer
Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu
Endpoints
Mon, 10/31/22 - 04:15 pm
Daiichi Sankyo
AstraZeneca
Enhertu
breast cancer
non-small cell lung cancer
Nuvalent reports positive data from Phase I/II NSCLC therapy trial
Clinical Trials Arena
Mon, 10/31/22 - 10:22 am
Nuvalent
non-small cell lung cancer
NVL-520
clinical trials
GSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancement
Fierce Biotech
Wed, 10/5/22 - 10:49 am
GSK
lung cancer
clinical trials
cobolimab
non-small cell lung cancer
FDA Approves Avastin Biosimilar for Six Types of Cancer
Pharmacy Times
Wed, 09/28/22 - 10:30 pm
FDA
biosimilars
Vegzelma
Avastin
non-small cell lung cancer
glioblastoma
metastatic colorectal cancer
cervical caner
metastatic renal cell carcinoma
FDA panel votes against Spectrum's lung cancer drug
Reuters
Thu, 09/22/22 - 11:54 pm
FDA
Spectrum Pharrmaceuticals
non-small cell lung cancer
poziotinib
Amgen’s Phase 3 win in lung cancer puts pressure on Mirati bid for speedy FDA nod
MedCity News
Wed, 08/31/22 - 10:23 am
Amgen
Lumakras
non-small cell lung cancer
clinical trials
Genprex to progress Phase I/II trial of non-small cell lung cancer therapy
Clinical Trials Arena
Tue, 08/16/22 - 12:15 pm
Genprex
clinical trials
Reqorsa
AstraZeneca
Tagrisso
non-small cell lung cancer
FDA converts Novartis' NSCLC drug to a full approval with confirmatory data
Endpoints
Thu, 08/11/22 - 11:22 pm
Novartis
Tabrecta
solid tumors
FDA
non-small cell lung cancer
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »